8-K/A: Monogram Technologies Reports Full Year 2024 Financial Results, Awaits FDA Decision on mBs TKA System

Monogram Technologies announces its full year 2024 financial results, highlights progress on FDA clearance for its mBs TKA System, and reports a strengthened balance sheet.

Summary

• Monogram Technologies Inc. reported its financial and operational results for the fourth quarter and year ended December 31, 2024.
• The company completed all supplemental testing and submitted its formal response to the FDA regarding the Additional Information Request (AIR) received on September 30, 2024.
• Monogram does not currently anticipate further requests for information from the FDA.
• A strategic collaboration with Shalby Limited is underway, including shipping a robot to India for clinical trial training and holding an Investigator Meeting.
• The company closed an upsized and oversubscribed $13 million public offering.
• Management and related parties completed open market purchases of MGRM common stock totaling $1 million.
• Monogram was named Orthopedic Joint Replacement Company of the Year 2024 by Medical Tech Outlook.
• Research and development expenses for 2024 were $8.8 million, compared to $10.6 million the prior year.
• Marketing and advertising expenses for 2024 were $2.1 million, compared to $3.0 million in the prior year.
• General & administrative expenses for 2024 increased to $4.4 million, from $4.1 million in 2023.
• Net loss was $16.3 million for the year ended December 31, 2024, compared to a net loss of $13.7 million for the year ended December 31, 2023.
• Cash and cash equivalents totaled $15.7 million as of December 31, 2024, compared to $13.6 million as of December 31, 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress on FDA submission, strengthened balance sheet, and strategic partnerships. However, the net loss and ongoing reliance on regulatory approvals temper the overall outlook.

Positives

• The company successfully submitted its response to the FDA's AIR, potentially paving the way for clearance of the mBs TKA System.
• The $13 million public offering strengthens the company's balance sheet and provides a cash runway for commercialization milestones.
• The collaboration with Shalby Limited provides an opportunity for international clinical trials and market expansion.
• Management's open market purchases of MGRM stock signal confidence in the company's future prospects.
• The company's cash position improved, providing financial flexibility.

Negatives

• The company reported a net loss of $16.3 million for the year ended December 31, 2024, which is higher than the $13.7 million loss in the previous year.
• The company is still awaiting FDA clearance for its mBs TKA System, and there is no guarantee of a favorable decision.

Risks

• The company's future success depends on obtaining FDA clearance for its mBs TKA System.
• Regulatory timelines can be variable, and there is no guarantee of timely clearance for clinical trials in India.
• The company faces risks inherent in the development, regulatory approval, and launch of new products.
• The company's lack of profitability and need for additional capital to grow its business pose ongoing risks.
• The outcome of pending or future litigation could negatively impact the company.

Future Outlook

The company is awaiting a response from the FDA for a clearance decision on the mBs TKA System and is working towards clinical trials in India. They are also exploring domestic and international relationships and continuing R&D to improve system performance.

Management Comments

• The fourth quarter was marked by continued progress toward the commercialization of our mBs Total Knee Arthroplasty (TKA) System, and a strengthened balance sheet to provide the cash runway to meet near-term commercialization milestones, said Ben Sexson, Chief Executive Officer of Monogram.
• We remain diligently focused on FDA clearance for our mBs TKA System 510(k) submission.
• We are also moving forward with our application to run an Outside the United States (OUS) clinical trial on the fully autonomous version of the system in collaboration with Shalby Limited.
• Strengthened by the cash runway needed to meet all near-term commercialization milestones, we are incredibly optimistic for 2025 and our mission to advance the standard of care in orthopedic medicine.

Industry Context

Monogram Technologies operates in the orthopedic robotics market, which is experiencing growth due to the increasing demand for minimally invasive surgical procedures and personalized implants. Competitors include companies like Stryker, Zimmer Biomet, and Smith & Nephew, which also offer robotic-assisted surgical systems for joint replacement.

Comparison to Industry Standards

• Monogram's focus on AI-driven robotics and personalized implants aligns with the industry trend towards precision medicine.
• The collaboration with Shalby Limited mirrors the strategy of other companies seeking to expand into emerging markets like India.
• The company's R&D spending is relatively low compared to larger competitors, reflecting its smaller size and focus on specific technology development.
• The net loss is typical for companies in the early stages of commercialization in the medical device industry.

Stakeholder Impact

• Shareholders will be impacted by the company's progress towards commercialization and financial performance.
• Employees will be affected by the company's growth and expansion plans.
• Orthopedic surgeons and patients stand to benefit from the potential advantages of the mBs TKA System.

Next Steps

• Obtain FDA clearance for the mBs TKA System.
• Obtain regulatory clearance to conduct clinical trials in India with Shalby Hospitals.
• Continue exploring domestic and international relationships.
• Continue R&D and product development to improve future competitiveness and expand to new applications.

Key Dates

Keywords

mBs TKA System, FDA clearance, orthopedic surgery, robotics, clinical trials, Shalby Limited, financial results, Monogram Technologies, MGRM